The present invention features, inter alia pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent compositions that include metyrapol and at least one additional pharmaceutically active agent compositions in which the agent targeting the HPA axis is itself new or modified (e.g., a bi specific antibody designed to traverse the blood brain barrier or a known compound redesigned by for example conjugation to a substance that traverses the blood brain barrier) and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.
